WO2003042243A2 - Peptides alk immunogeniques - Google Patents

Peptides alk immunogeniques Download PDF

Info

Publication number
WO2003042243A2
WO2003042243A2 PCT/EP2002/012764 EP0212764W WO03042243A2 WO 2003042243 A2 WO2003042243 A2 WO 2003042243A2 EP 0212764 W EP0212764 W EP 0212764W WO 03042243 A2 WO03042243 A2 WO 03042243A2
Authority
WO
WIPO (PCT)
Prior art keywords
alk
peptide
seq
hla
cells
Prior art date
Application number
PCT/EP2002/012764
Other languages
English (en)
Other versions
WO2003042243A3 (fr
Inventor
Carlo Gambacorti-Passerini
Lorena Passoni
Original Assignee
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
St. Jude Children's Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, St. Jude Children's Research Hospital filed Critical Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
Priority to EP02787687A priority Critical patent/EP1444261B1/fr
Priority to AT02787687T priority patent/ATE308565T1/de
Priority to AU2002352011A priority patent/AU2002352011A1/en
Priority to DE60207103T priority patent/DE60207103T2/de
Publication of WO2003042243A2 publication Critical patent/WO2003042243A2/fr
Publication of WO2003042243A3 publication Critical patent/WO2003042243A3/fr
Priority to CY20061100051T priority patent/CY1105357T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to immunogenic peptides derived from Anaplastic Lymphoma Kinase (ALK) that can be used in the immunotherapy of tumors. More specifically, the invention provides cytotoxic T-lymphocyte (CTL)-epitopes from ALK protein, in vivo and in vitro methods, using the ALK peptides of the invention, for activating ALK-specific CTLs and for stimulating an immune response against ALK positive tumors, and pharmaceutical compositions suitable for use in such methods.
  • ALK Anaplastic Lymphoma Kinase
  • TAAs tumor-associated antigens
  • a major issue in the development of efficient vaccination protocols is the identification of the appropriate and effective TAAs, able to induce an immune response that will affect tumor growth.
  • the ideal target for immune destruction is a tumor specific protein that is not expressed in normal cells and is essential for the malignant phenotype (Gilboa E., (1999) Immunity, 11 : 263-270).
  • ALK is a receptor tyrosine kinase identified for the first time by Morris et al.
  • NPM/ALK oncogenic anaplastic lymphoma kinase fusion protein
  • This fusion protein is composed of the N-terminal portion of the nuclear phosphoprotein Nucleophosmin (NPM) linked to the entire intracellular portion of ALK, which contains its kinase catalytic domain.
  • NPM nuclear phosphoprotein Nucleophosmin
  • NPM is a "housekeeping" gene that is ubiquitously expressed in normal cells
  • ALK expression is restricted in embryonic and adult mouse to the Central Nervous System (CNS) (Iwahara T et al, ( ⁇ 991) Oncogene, 14: 439-449; Morris S. et al , (1997) Oncogene, 14: 2175-2188).
  • CNS Central Nervous System
  • ALK was detected at low levels in some pericytes and scattered glial cells in specific areas of the CNS.
  • ALK is not normally expressed in lympho- hematopoietic tissues (Pulford K et al, (1997) Blood, 89: 1394-1404).
  • ALK is ectopically expressed at high levels in lymphoid cells and its constitutive tyrosine kinase activity leads to deregulated lymphocyte growth (Bischof D. et al, (1998) Mol. Cell Biol, 18: 6951-6961).
  • the present invention provides peptides derived from anaplastic lymphoma kinase (ALK) which induce MHC class I restricted cytotoxic lymphocyte responses against tumor cells expressing the NPM/ALK fusion protein as a result of a t(2;5) translocation.
  • ALK anaplastic lymphoma kinase
  • the disclosed peptides are derived from three regions of the fusion protein, including the kinase domain, a region located downstream of the kinase domain and the C- terminal portion of the kinase.
  • the ALK epitopes are furhter characterized by spontaneous processing and presentation at the surface of tumor cells.
  • translocated ALK is a widely expressed tumor-associated antigen characteristic of ALK-positive lymphomas (e.g., alkomas), neuroblastomas and ALK-expressing neoplasias. This feature makes ALK an attractive target for vaccination protocols.
  • the invention provides seven (e.g., SEQ ID NOS: 1-7) HLA-A* 0201 -binding ALK peptides.
  • the disclosed peptides are characterized by in vivo immunogenicity in HLA-A*0201 transgenic mice and the ability to stimulate MHC class I restricted ALK-specific CTLs in vitro using human peripheral blood lymphocytes obtained from healthy donors.
  • the invention also provides a pharmaceutical composition comprising an ALK peptide of the invention in combination with at least one pharmaceutically acceptable excipient.
  • the invention provides a vaccine composition.
  • An alternative embodiment of the invention provides antibodies that selectively recognize the epitopes represented by the disclosed ALK peptides.
  • the ALK-specific antibodies encompassed by the invention include both monoclonal and polyclonal antibodies and active fragments thereof.
  • the invention further provides a method for inducing a cytotoxic response against tumor cells expressing an ALK antigen, which comprises contacting T lymphocytes with an ALK peptide under conditions suitable for CTL activation.
  • the invention describes a method in which lymphocytes are contacted with antigen presenting cells comprising (e.g., carrying or presenting) a peptide of the invention bound to an HLA- A*0201 molecule.
  • the invention describes a method which comprises contacting lymphocytes directly with an ALK peptide of the invention.
  • the invention relates to isolated antigen presenting cells, such as but not limited to HLA-A2.1 positive dendritic cells or autologus peripheral blood mononuclear cells, carrying an ALK peptide of the invention, as well as to isolated T lymphocytes which are capable of selectively binding a complex comprising an HLA class I molecule and an ALK peptide.
  • isolated antigen presenting cells such as but not limited to HLA-A2.1 positive dendritic cells or autologus peripheral blood mononuclear cells, carrying an ALK peptide of the invention, as well as to isolated T lymphocytes which are capable of selectively binding a complex comprising an HLA class I molecule and an ALK peptide.
  • the invention provides a method for treating a subject having a disorder characterized by expression of an ALK antigen, such as an alkoma, a neuroblastoma or an ALK-expressing neoplasia, which comprises administering to the subject an effective amount of one of the ALK peptides of the invention, or a functional variant thereof.
  • An alternative treatment method describes administering either antigen presenting cells carrying one of the ALK peptides, or autologous T lymphocytes specific (e.g., capable of binding to or interacting with) for complexes of an HLA-A*0201 molecule associated with one of the ALK peptides or a functional variant thereof.
  • the invention provides isolated nucleic acid molecules encoding the ALK peptides of the invention, chimeric genes comprising an isolated nucleic acid molecule of the invention under the control of a heterologous promoter, and expression vectors comprising a chimeric gene of the invention.
  • These embodiments of the invention find utility in establishing a host vector system for the production of the ALK peptides of the invention, and for the isolation of host cells and cell lines comprising a chimeric gene of the invention.
  • FIGS 1A and IB Induction of anti-ALK specific effectors in healthy donor Peripheral Blood Lymphocytes (PBLs). PBLs obtained from five donors (DG, ZB, SA, PG and BF) were activated with autologous peptide- pulsed DCs and restimulated weekly with peptide-loaded autologous monocytes. The resulting T-cell bulk cultures were tested for antigen specificity starting at the third round of stimulation. Cytotoxic activity was determined in a standard 51 Cr-relese assay at an E:T ratio of 50:1 ( ⁇ ) and 25: 1 (D) using as targets either T2 cells pulsed with 5 ⁇ M of cognate peptide or irrelevant influenza matrix- derived peptide (FLU) (Fig. 1A) or NPM/ALK positive lymphoma cell lines SU-DHL1 and SUP-M2 (Fig. IB). Results of one representative experiment out of two performed are shown.
  • PBLs Peripheral Blood Lymphocytes
  • FIGS. 2A and 2B IFN- ⁇ release by in v/ ⁇ r ⁇ -induced anti-ALK CTL lines.
  • Autologous EBV-transformed B cells (LCL) (Fig. 2A) and T2 cells (Fig. 2B) were pulsed with 5 ⁇ M p280-89 and p376-85 peptides, respectively as well as influenza matrix peptide (FLU: irrelevant peptide) and were then used as stimulator in an IFN- ⁇ release assay.
  • FIGS. 3A and 3B Peptide sensitivity of in vi ⁇ r ⁇ -induced ALK- specific CTLs.
  • T2 cells were incubated with titrated amounts of p280-89 (Fig. 3A) and p376-85 (Fig. 3B) peptides as well as influenza matrix peptide (FLU) and were then used as stimulator in an IFN- ⁇ release assay using CTL lines prepared from donors ZB and DG and SA. Results of one representative experiment out of two performed are shown.
  • FIGS 4A - 4C Specific lysis of ALCL cell lines endogenously expressing NPM/ALK. p280-89-specific CTL lines generated from donors DG (Fig. 4A) and ZB (Fig. 4B), and ⁇ 376-85-specific CTL lines generated from donor SA (Fig. 4C) efficiently recognize and lyse HLA-matched ALCL lymphoma cell lines (SU-DHL1 and SUP-M2) endogenously expressing NPM/ALK. Lysis was inhibited in the presence of anti-HLA-A2 mAb CRl 1.351 and no activity was detected against HLA-A2.1+ cell lines FM3 (melanoma), HCT-116 (colon carcinoma) and MCF-7 (breast carcinoma).
  • FM3 melanoma
  • HCT-116 colon carcinoma
  • MCF-7 breast carcinoma
  • IMR-32 (HLA-A2.1+/ALK+), SK-N-SH (HLA-A2.1-/ALK+) and NB-5 (HLA-A2.1+/ALK-) cell lines were used as targets in a standard 51 Cr-relese assay using ALK peptide-specific ALK cell lines prepared from donors DG and ZB (p280-89-specific CTL lines) (Fig. 5A) and donor SA (p375-86- specific CTL line) (Fig. 5B).
  • the invention is based on the identification of novel CTL epitopes within the NPM/ALK fusion protein.
  • tumor-associated CTL epitopes have been identified in the ALK tyrosine kinase domain, having in common the following properties: a) binding to HLA-A2.1 molecules, (b) immunogenicity in vivo in HLA-A*0201 transgenic mice, (c) in vitro stimulation of specific CTL responses using PBLs from healthy donors, (d) spontaneous processing and presentation at the surface of tumor cells.
  • ALK protein is not expressed by normal cells, except at low levels in some CNS cells, the inventors investigated whether ALK kinase could be a target for antigen-specific cell-mediated immunotherapy.
  • a panel of ALK-derived peptides were thus tested for their binding affinity to HLA- A*0201 molecules and then the binding peptides were assessed for their capacity to elicit a specific immune response mediated by Cytotoxic T- Lymphocytes (CTLs) both in vivo, in HLA-A*0201 transgenic mice, and in vitro in the peripheral blood lymphocytes (PBLs) from healthy donors.
  • CTLs Cytotoxic T- Lymphocytes
  • peptides able to bind HLA-A*0201 molecule and showing in vivo immunogenicity were thus identified.
  • peptides p280-89 (SLAMLDLLHV, SEQ ID NO: 1), p376-85 (GVLLWEIFSL, SEQ ID NO: 2) p281-89 (LAMLDLLHV, SEQ ID NO: 3), p282-90 (AMLDLLHVA, SEQ ID NO: 4), and p377-85 (VLLWEIFSL, SEQ ID NO: 5) laid within the kinase domain, p456-65 (ALPIEYGPLV, SEQ ID NO: 6) was downstream of the kinase domain and p621-629 (SLTANMKEV, SEQ ID NO: 7) was in the C- terminal portion of the protein.
  • Two HLA-A*0201 restricted CTL epitopes, p280-89 (SLAMLDLLHV -
  • the anti-ALK specific CTL repertoire is unlikely to react against normal CNS cells, because the CNS is an immunologically privileged site where, under physiological conditions, antigens are not exposed to the immune system. More importantly, the scarce level of expression in normal CNS is most likely too low to ensure CTL recognition as shown with human MAGE-specific and murine p53-specific CTLs. In contrast, the high level of expression of NPM/ALK, driven by the strong NPM promoter, results in a substantial amount of NPM/ALK processing by the proteosome, thereby leading to a significant expression of ALK-derived epitopes at the cell surface.
  • ALK is required for neoplastic transformation of lymphoid cells, tumor escape phenomena by ALK antigen loss variants are unlikely to occur.
  • Translocated ALK is expressed in approximately 83% and 31% of ALCL children and adult respectively (Drexler HG. et al, Leukemia. 2000; 14: 1533- 1559), indicating that ALK is a stable lymphoma-specific hallmark.
  • ALK-positive lymphoma or "Alkoma" has been recognized as a distinct tumor entity (Benharroch D et al, Blood 1998; 91 : 2076-2084).
  • ALK broad expression is not restricted to one or a few patients, as in the case of point-mutated oncogenes. This feature makes its use in vaccination protocols more easily and widely applicable.
  • ALK specific CTLs have been demonstrated to efficiently kill ALK+ neuroblastoma tumor lines.
  • the killing of neuroblastoma cells by a CTL response specific for ALK epitopes reveals the potential of ALK as a shared tumor antigen for multiple malignancies.
  • HLA- A*0201 -restricted peptides selected from SEQ ID NOS: 1-7.
  • Peptides of SEQ ID NO: 1 and 2 which were found to strongly activate a cytotoxic response, are preferred.
  • the peptides of the invention can be prepared in a wide variety of ways. For example, they can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. For example, see Stewart and Young, ( ⁇ 984)Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co.; Tarn et al., J. Am. Chem. Soc, (1983)105:6442; Merrifield, The Peptides, Gross and Whynhofer eds. Academic Press, (1979)New York, pp. 1-284, each of which is hereby incorporated by reference.
  • the peptide amino acid sequences according to the invention can be modified by deletion, substitution or addition of one or more residues, provided that the derivatives thus obtained have at least the same, preferably a higher immunogenic activity than the unmodified peptides.
  • the latter can also be conjugated with lipids, glycosyl-residues or other peptides, to obtain improved properties such as higher affinity for the HLA molecule, higher immunogenicity or better bioavailability after administration.
  • the peptides can also be conjugated with different epitopes known to induce a T "helper" cellular response through the same or a different class of MHC molecules.
  • the invention also includes isolated nucleic acid molecules encoding an HLA- A* 0201 -binding ALK peptide selected from the group consisting of SEQ ID NOS: 1-7, or a functional variant thereof.
  • the choice of a specific nucleotide sequence coding for an ALK peptide will depend on the selected expression system and can be varied due to degeneracy of the genetic code.
  • the invention also embraces an expression vector in which the pertinent nucleic acid sequence is operably linked to a heterologous promoter, as well as a host vector system for the production of a peptide which comprises said expression vector in a suitable host cell, and a cell line comprising the nucleic acid molecule encoding an ALK peptide.
  • the ALK peptides of the invention can be produced in vitro or in vivo as a consequence of the use of recombinant DNA technology to produce a nucleotide sequence which encodes an ALK peptide of interest.
  • a suitable coding sequence can be inserted into an expression vector, and the expression vector introduced into an appropriate host cell, by transformation or transfection, and the resulting host cell cultivated under conditions suitable for expression of the coding sequence and production of the encoded peptide.
  • nucleic acid sequence that encodes an ALK-peptide of the invention.
  • Suitable nucleotide sequence can be back-translated using codons that encode the amino acids of any one of the ALK peptides disclosed herein that has been demonstrated to be immunogenic for human lymphocytes.
  • the coding sequence for peptides of the length contemplated herein can be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al., (1981) J. Am. Chem. Soc, 103:3185. Chemical synthesis provides the opportunity to modify the coding sequence to include appropriate linkers designed to facilitate ligation into commonly available and well-known expression vectors. Numerous vectors and suitable host systems are widely available in the art. Generally speaking, for expression of the peptide, the coding sequence will be provided with operably linked stop and start codons, promoter and terminator regions and usually a replication system to provide an expression vector for a particular cellular host. For example, bacterial, yeast or mammalian host cells may be used in combination with appropriate vectors and control sequences.
  • the invention is directed to pharmaceutical compositions containing an effective amount of a peptide herein described.
  • the pharmaceutical compositions for therapeutic treatment are intended for parenteral, oral or local administration.
  • the pharmaceutical compositions are administered parentally, e.g., intravenously, intramuscularly.
  • Actual methods for preparing and parentally administering the pharmaceutical compositions of the invention will be known or apparent to one of skill in the art and are described in more detail in for example, Remington's Pharmaceutical Science, 17 th ed., Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference.
  • said compositions are in the form of vaccines, particularly suited for preventive vaccination of subjects with cancer susceptibility or for therapeutic vaccination of neoplastic patients.
  • the vaccine compositions will contain one or more pharmaceutically acceptable excipients.
  • Effective amounts means an amount sufficient to elicit an effective CTL response against a tumor cell. Such amount will depend on the specific peptide, on the route and type of administration, on the severity of the pathology to be treated and on the general conditions of the patient; suitable amounts will usually vary from 1 to 1000 ⁇ g, preferably from 100 to 300 ⁇ g divided in three or more administrations at 1 month intervals or more frequently. General procedures for the preparation and use of vaccines are known to those skilled in the art (see for example Paul, Fundamental Immunology, Raven Press, New York (1989) or Cryz, S. J., Immunotherapy and Vaccines, VCH Verlagsgesselshaft, 1991).
  • Vaccines are usually prepared in the form of injectable suspensions or solutions, but they can also be used in the form of solid or liposome preparations.
  • the immunogenic ingredients are preferably mixed with one or more pharmaceutically acceptable excipients, such as emulsifiers, buffering agents or adjuvants enhancing the efficacy of the vaccine.
  • the vaccine can be administered according to a single or multiple dosage scheme. In case of multiple dosage, 1 to 10 separated doses are provided, each containing an antigen amount ranging from 1 to 1000 ⁇ g, followed by booster doses at different time intervals necessary to maintain or strengthen the immune response and, if necessary, a further dose after several months. In each case, the treatment regimen will depend on the response of the patient and on tumor progression.
  • compositions and methods of the invention may also be employed for ex vivo therapy.
  • ex vivo therapy is meant that therapeutic or immunogenic manipulations are performed outside of the body.
  • lymphocytes or antigen presenting cells may be removed from a patient and treated with high doses of the subject peptides, providing a stimulatory concentration of peptide in the cell culture medium far in excess of levels that could be accomplished or tolerated by the patient if the peptide were to be administered in vivo.
  • the cell population e.g., cytotoxic T lymphocytes, bulk lymphocyte populations or antigen presenting cells
  • a patients cells may be exposed to vectors that carry the a nucleic acid sequence that encodes an ALK peptide of the invention. Once transfected, the cells may either be propagated in vitro until a desired cell density is achieved or returned directly to the patient for in vivo expansion.
  • the invention provides a method for inducing a cytotoxic response against tumor cells expressing one or more ALK epitopes, which comprises contacting T lymphocytes with the peptides of the inventions in conditions suitable for the activation of cytotoxic T cells.
  • Suitable conditions for achieving the desired cytotoxic effects comprise direct exposure of T lymphocytes to the peptide in culture or to antigen presenting cells (APC) expressing HLA class I molecules previously loaded with (e.g., carrying) the peptide.
  • Suitable APCs are peripheral blood autologous mononuclear cells (PBMC), dendritic cells, macrophages or activated B cells.
  • APC culture is added with the peptide for a time sufficient for binding and then with a cell population containing T lymphocytes which are thus activated to proliferate and to mediate cytotoxicity.
  • Lymphocytes can be taken from the patient under treatment and, after activation, re-injected into the same patient.
  • Peptide/APC binding can be increased by previously "stripping" the histocompatibility molecules present on APCs.
  • patient APCs can be genetically engineered to express the HLA-A*0201 allele.
  • the allele HLA-A2.1 is accessible in GenBank No.: M84379, protein sequence No.: PID g403144.
  • the culture medium can contain one or more cytokines to increase the activation of CD8+ precursors.
  • lymphocytes Prior to their reintroduction into the patient, lymphocytes can be purified for example through an affinity column derivatized with a specific ligand.
  • T lymphocytes can be selectively enriched by employing an affinity column derivitized with a reagent, such as an antibody or active fragment thereof, that binds to CD3, CD8 or CD4.
  • a further object of the invention are antigen presenting cells (APCs), preferably dendritic cells, carrying (presenting) a peptide of the invention.
  • APCs antigen presenting cells
  • the term carrying refers to the molecular complex that results from a binding interaction between an ALK peptide of the invention and an HLA class I molecule.
  • the APCs can be genetically modified, for example by transfection with suitable viral or retro viral vectors, so as to confer the requisite, intracellularly process and molecular species required to express the relevant ALK peptide in a MHC Class I restricted manner on the cell surface.
  • the APCs can be loaded with the peptide in culture.
  • the invention also provides a cytotoxic T cell specifically recognizing a complex formed by an HLA class I molecule, preferably HLA-A*0201 , and a peptide selected from SEQ ID NOS: 1-7, preferably from SEQ ID NOS: l and 2.
  • the cytotoxic T-lymphocyteline can be obtained by selection, starting from a lymphocyte pool, of cells capable of activating upon exposure to tumor cells containing ALK antigenic determinants.
  • the invention provides a method for treating a subject having a disorder characterized by expression of ALK antigens, which comprises administering to the subject an effective amount of an ALK peptide selected from SEQ ID NOS: 1-7, preferably from SEQ ID NOS: l or 2, or a functional variant thereof, or an amount of APCs carrying such an ALK peptide, or of autologous T lymphocytes specific for complexes of an HLA- A*0201 molecule and an ALK peptide of the invention, or a functional variant thereof.
  • Disorders that can benefit from such a treatment include, but are not limited to, ALK-positive lymphomas and neuroblastoma.
  • a further embodiment of the invention relates to antibodies, fragments or derivatives thereof, recognizing and binding the peptides of the invention.
  • Methods for producing antibodies to specific peptides are well known in the art (Kohler and Milstein, Nature 256 (1975), 494, or J.G.R. Hurrel, Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press Inc., Boco Raton, FL, 1982).
  • the antibodies according to the invention include monoclonal and polyclonal antibodies as well as their F(ab')2, Fab, Fv or scFv fragments.
  • EXPERIMENTAL The present invention may be better understood with reference to the following examples. These examples are intended to be representative of specific embodiments of the invention, and are not intended as limiting the scope of the invention.
  • EXAMPLE 1 HLA-A*A0201 binding assays To determine the binding ability of predicted peptides to HLA-A*0201 molecules, an in vitro cellular binding assay was performed using the TAP- deficient cell line T2. As used herein, the term TPA refers to "transporter associated with antigen presentation.” T2 cells are HLA-A*0201 positive, TAP-negative human cells.
  • T2 cells were incubated with 100 ⁇ M of peptide in serum-free RPMI 1640 supplemented with 5 ⁇ g/ml of human ⁇ 2 m (Fluka, Buchs, Germany) for 18 hrs at 37°C.
  • HLA-A*0201 expression was then measured by flow cytometry using the anti-HLA-A2.1 mAb BB7.2 followed by incubation with FITC-conjugated F(ab') 2 goat anti-mouse Ig (BioSource, Camarillo, CA).
  • FI Fluorescence Index
  • T2 cells (lOVml) were incubated overnight with 100 ⁇ M of each peptide in serum free RPMI 1640 supplemented with 100 ng/ml of human ⁇ 2 m at 37°C. Cells were then washed four times to remove free peptides, incubated for 1 hr with 10 ⁇ g/ml of Brefeldin A (Sigma-Aldrich, France) in order to block cell surface expression of newly synthesized HLA-A*0201 molecules, washed and incubated at 37°C for 0, 2, 4, 6, or 8 hours. Subsequently, cells were stained with anti-HLA-A2.1 mAb BB7.2.
  • peptide induced HLA- A*0201 expression was calculated as: mean fluorescence value of peptide incubated T2 cells/mean fluorescence value T2 cells in the absence of the peptide.
  • HHD mice Human Human D transgenic mice have been previously described. Pascolo, S. et al, (1997) J. Exp. Med., 185:2043; Firat, H., et al, (1999) Eur. J. Immunol, 29: 3112). HHD mice are deficient for the ⁇ _- microglobulin ( ⁇ 2 m) gene and for mouse MHC class I H-2D b molecules and are transgenic for a chimeric HLA-A*0201/D b molecule.
  • HLA-A*0201 monochain composed of a chimeric heavy chain ( ⁇ l and ⁇ 2 domains of human HLA- A* 0201, ⁇ 3 and intra-cellular domains of D b ) linked by its N-terminus to the C-terminus of the human ⁇ 2 -microglobulin ( ⁇ 2 m) light chain by a 15 amino acid peptide.
  • the chimeric molecule is the only class I molecule that is serologically detected on the surface of HHD cells.
  • mice were housed in a temperature-controlled, light cycled room. All in vivo experiments were performed in accordance with local ethical guidelines.
  • HHD mice To evaluate the in vivo immunogenic potential of ALK-derived high- affinity binding peptides, we immunized H-2D b / ⁇ , ⁇ 2m "/" , HLA-A*0201 monochain transgenic (HHD) mice. In these mice, the peripheral CD 8+ T cell repertoire is educated, both at the thymic and peripheral levels, with transgenic HLA class I human molecules. Therefore, the HHD mouse is a useful animal model to assess the ability of individual peptides to induce HLA-A* 0201 -restricted CTL responses in vivo (Firat H. et al, (1999) Eur J Immunol. 29: 3112-3121 ; Minev B.
  • HHD mice were injected subcutaneously at the base of the tail with 100 ⁇ g of peptide emulsified in Incomplete Freund's Adjuvant (IFA) in the presence of 140 ⁇ g of I A restricted HBV core antigen-derived T-helper epitope (pl28-40; TPPAYRPPNAPIL). After 11 days, spleen cells from primed mice (5xl0 7 cells in 10ml) were restimulated in vitro with 10 ⁇ M of peptide. On day 6 of culture, cells were tested for specific cytotoxicity in a 4- hrs 51 Cr-release assay using as targets RMA-S/HHD cells pulsed with l ⁇ M peptide or alone.
  • IFA Incomplete Freund's Adjuvant
  • NPM/ALK sequence is referred to NPM/ALK sequence.
  • mice **** R/T, responder versus tested mice. Mice were considered as responders when the specific lysis of peptide-loaded RMA-S/HDD target cells was at least 15% above the lysis of RMA-S/HDD.
  • PBMC peripheral blood mononuclear cells
  • GM-CSF granulocyte-macrophage colony- stimulating factor
  • the surface phenotype of monocyte-derived DCs was determined by single-color flow cytometry using the following mAbs: fluorescein-coniugated anti-CD la (Valter Occhiena, Torino, Italy), anti-CD86 (CALTAG, Burlingame, CA), anti-CD83 (CALTAG, Burlingame, CA), anti-CD 14 (Becton Dickinson) and rhodamine-conjugated anti-CD80 (Becton Dickinson). DCs were used to prime autologous PBL as follows.
  • DCs were pulsed with 10 ⁇ M peptide for 2 hrs at 37°C, irradiated at 30 Gy and added to autologous PBLs at a ratio variable from 3: 1 to 6: 1 (PBL:DC).
  • PBLs (36xl0 6 total) were cultured at 1.5xl0 6 cells/2ml of Culture Medium (CM: 50% RPMI 1640 / 50% X-VIVO (BioWhittaker, Walkkersville, MA)) supplemented with 10% of heat- inactivated autologous plasma and 10 ng/ml IL-7 (R&D Systems, Minneapolis, MN) in the presence of autologous peptide-loaded DCs.
  • CM 50% RPMI 1640 / 50% X-VIVO (BioWhittaker, Walkkersville, MA)
  • lymphocytes were restimulated with irradiated (30Gy) autologous peptide-loaded monocytes in CM supplemented with 10% of heat- inactivated autologous plasma. After 24-48 hrs 10 IU/ml IL-2 (Chiron Co., Emeryville, CA) and 10 ng/ml IL-7 was added to the CM. Lymphocytes were then restimulated weekly in the same way. Starting from the forth round of stimulation, the specificity of the resulting T-cell lines was evaluated weekly in a cytolytic assay.
  • CD8+ T-cells were isolated from the bulk culture by CD4+ cells negative depletion using mAb-coated beads (Dynal Dynabeads, Oxoid, Oslo, Norway) and the CTL lines were maintained in culture in RPMI 1640 containing 10% human AB serum supplemented with 50 U/ml IL-2 in the presence of irradiated (70Gy) PBMCs as feeder.
  • cytokine release assay 10 5 target cells (EBV-transformed B cells and TAP-/- T2 cells) and 10 5 lymphocytes were incubated overnight in round- bottomed microtiter plates in 250 ⁇ l/well total volume of RPMI 1640 supplemented with 10% FCS. Plates were then centrifuged and 200 ⁇ l aliquot of supernatant was removed from each well. IFN- ⁇ level was determined by ELISA (MABTECH, Nacka, Sweden). Results
  • peptide-pulsed autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) were used after their in vitro maturation was confirmed by flow cytometric analysis of DC-specific cell surface markers.
  • T lymphocyte specificity for ALK peptides was evaluated by determining antigen-restricted lysis of peptide loaded T2 cells (Fig. 1 A) and NPM/ALK-positive lymphoma cell lines (Fig. IB).
  • At least one out of the three donors tested were found to be responders to stimulation with peptides p280-89 (SEQ ID NO: 1), p376-85 (SEQ ID NO: 2), p377-85 (SEQ ID NO: 5) and p456-65 (SEQ ID NO: 6) (donors DG, ZB, SA, PG, and BF) ( Figures 1A and IB).
  • No specific CD8 reactivity was detected in the cell lines generated from donor PBLs stimulated with peptides p281-89 (SEQ ID NO: 3), p282-90 (SEQ ID NO: 4), and p621-29 (SEQ ID NO: 7) (data not shown).
  • a titration assay was performed to further assess the sensitivity and competence of CTLs in recognizing the antigen.
  • T2 cells were pulsed with p280-89, p376-85 or FLU peptides at different concentrations, and then used as stimulators in a cytokine release assay.
  • p280-89 specific CTLs maximal production of IFN- ⁇ was reached with only 10 nM of peptide, indicating high affinity of recognition and antigen concentration-dependent IFN- ⁇ production (Figure 3 A).
  • the CTL line from donor SA, specific for ALK peptide p376-85 exhibited a lower level of IFN- ⁇ release (maximal release at 100 nM), indicating a lower efficiency for T cell stimulation (Figure 3B).
  • ALK-derived peptides demonstrated to be immunogenic in vivo and in vitro, were also naturally processed on human tumor cells, we examined the ability of p280-89-specific and p376-85-specific CTLs to lyse HLA-A2.1+ ALCL lymphoma cell lines, SU-DHL1 and SUP- M2, expressing the chimeric protein NPM/ALK. ALK specific CTLs killed these tumor lines and their lytic activity was inhibited by the presence of anti- HLA-A2 mAb CRl 1.351.
  • Native ALK tyrosine kinase expression has also been demonstrated in cell lines and tumors of neural origins such as neuroblastoma (Lamant L, et ⁇ /.(2000) Am. J. Pathol, 156: 1711-1721). Because p280-89 and p376-85 peptides lie within the kinase domain, which is present in both native and translocated ALK, we used neuroblastoma cell lines as targets in cytotoxic experiments to further verify the natural processing of these two epitopes. Due to the limited expression of class I MHC molecules characterizing neuroblastomas that could interfere with the antigen recognition by CTLs, we treated tumor cells with INF- ⁇ before their use as targets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des peptides immunogéniques provenant de kinase de lymphome anaplastique (ALK), des procédés in vivo ou in vitro permettant d'activer des CTL spécifiques à ALK, et de stimuler une réponse immunitaire contre des tumeurs, ainsi que des compositions pharmaceutiques contenant des peptides ALK pour une immunothérapie tumorale.
PCT/EP2002/012764 2001-11-15 2002-11-14 Peptides alk immunogeniques WO2003042243A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02787687A EP1444261B1 (fr) 2001-11-15 2002-11-14 Peptides alk immunogeniques
AT02787687T ATE308565T1 (de) 2001-11-15 2002-11-14 Immunogene alk (anaplastic lymphoma kinase) peptide
AU2002352011A AU2002352011A1 (en) 2001-11-15 2002-11-14 Immunogenic alk (anaplastic lymphoma kinase) peptides
DE60207103T DE60207103T2 (de) 2001-11-15 2002-11-14 Immunogene alk (anaplastic lymphoma kinase) peptide
CY20061100051T CY1105357T1 (el) 2001-11-15 2006-01-17 Ανοσογονα πεπτιδια alk (αναπλαστικη κιναση λεμφωματος)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/008,377 2001-11-15
US10/008,377 US20030157101A1 (en) 2001-11-15 2001-11-15 Immunogenic ALK peptides

Publications (2)

Publication Number Publication Date
WO2003042243A2 true WO2003042243A2 (fr) 2003-05-22
WO2003042243A3 WO2003042243A3 (fr) 2004-03-25

Family

ID=21731292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012764 WO2003042243A2 (fr) 2001-11-15 2002-11-14 Peptides alk immunogeniques

Country Status (9)

Country Link
US (1) US20030157101A1 (fr)
EP (1) EP1444261B1 (fr)
AT (1) ATE308565T1 (fr)
AU (1) AU2002352011A1 (fr)
CY (1) CY1105357T1 (fr)
DE (1) DE60207103T2 (fr)
DK (1) DK1444261T3 (fr)
ES (1) ES2250727T3 (fr)
WO (1) WO2003042243A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2042191A1 (fr) * 2007-09-28 2009-04-01 Roberto Chiarle Kinase de lymphome anaplastique (ALK) en tant qu'oncoantigène pour une vaccination contre le lymphome
EP2289532A1 (fr) * 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Peptides épitopes derivés d'un récépteur de facteur de croissance endothéliale vasculaire 1 et vaccins contenant ces peptides

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11623002B2 (en) 2016-01-29 2023-04-11 Elicio Therapeutics, Inc. ALK polypeptides and methods of use thereof
JP2022548371A (ja) * 2019-09-18 2022-11-18 ザ チルドレンズ メディカル センター コーポレーション 未分化リンパ腫キナーゼ（ａｌｋ）がんワクチンおよび使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015331A1 (fr) * 1993-12-03 1995-06-08 St. Jude Children's Research Hospital PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015331A1 (fr) * 1993-12-03 1995-06-08 St. Jude Children's Research Hospital PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION
US6174674B1 (en) * 1993-12-03 2001-01-16 St. Jude Children's Research Hospital Method of detecting a chromosomal rearrangement involving a breakpoint in the ALK or NPM gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2000 (2000-11-16) PASSONI LORENA ET AL: "In vitro induction of primary HLA class I-restricted immune response against ALK kinase." Database accession no. PREV200100312465 XP002243620 & BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), page 338a 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000 ISSN: 0006-4971 *
GAMBACORTI-PASSERINI C ET AL: "Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers." CLINICAL CANCER RESEARCH, vol. 3, no. 5, May 1997 (1997-05), pages 675-683, XP001149115 ISSN: 1078-0432 *
PASSONI LORENA ET AL: "ALK as a novel lymphoma-associated tumor antigen: Identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes." BLOOD, vol. 99, no. 6, 15 March 2002 (2002-03-15), pages 2100-2106, XP002243621 March 15, 2002 ISSN: 0006-4971 *
PULFORD KAREN ET AL: "Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma." BLOOD, vol. 96, no. 4, 15 August 2000 (2000-08-15), pages 1605-1607, XP002243622 ISSN: 0006-4971 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289532A1 (fr) * 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Peptides épitopes derivés d'un récépteur de facteur de croissance endothéliale vasculaire 1 et vaccins contenant ces peptides
US7919099B2 (en) 2005-02-28 2011-04-05 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US8257711B2 (en) 2005-02-28 2012-09-04 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US8663647B2 (en) 2005-02-28 2014-03-04 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
EP2042191A1 (fr) * 2007-09-28 2009-04-01 Roberto Chiarle Kinase de lymphome anaplastique (ALK) en tant qu'oncoantigène pour une vaccination contre le lymphome
US8980287B2 (en) 2007-09-28 2015-03-17 Roberto CHIARLE Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination
US9650614B2 (en) 2007-09-28 2017-05-16 Roberto CHIARLE Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination

Also Published As

Publication number Publication date
AU2002352011A1 (en) 2003-05-26
DK1444261T3 (da) 2006-03-20
CY1105357T1 (el) 2010-03-03
DE60207103D1 (en) 2005-12-08
ATE308565T1 (de) 2005-11-15
ES2250727T3 (es) 2006-04-16
WO2003042243A3 (fr) 2004-03-25
DE60207103T2 (de) 2006-10-05
EP1444261A2 (fr) 2004-08-11
EP1444261B1 (fr) 2005-11-02
US20030157101A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
Tsang et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
EP2470200B1 (fr) Immunogènes cytotoxiques induisant des lymphocytes t pour prévenir, traiter et diagnostiquer un cancer
EP2043679A2 (fr) Immunogenes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prevention, du traitement et du diagnostic du cancer
EP2061503A2 (fr) Immunogènes inducteurs de la production de lymphocytes t cytotoxiques pour la prévention, le traitement et le diagnostic du cancer
JP4900884B2 (ja) 腫瘍抗原
JPH11502710A (ja) 悪性腫瘍の予防または処置のためのｈｅｒ−２／ｎｅｕタンパク質の細胞内ドメイン
JP2007516966A (ja) 合成ｈｌａ結合ペプチド類似体及びその使用方法
CA2207736A1 (fr) Activation in vivo de lymphocytes t cytotoxiques specifiques de tumeurs
US20100074945A1 (en) Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
WO2009036246A2 (fr) Immunogènes qui induisent des lymphocytes t cytotoxiques et leur utilisation dans la prévention, le traitement et le diagnostic du cancer
CA2286477A1 (fr) Compositions provoquant une reaction immunitaire contre des antigenes associes a une tumeur et methode afferente
Nawrocki et al. Genetically modified tumour vaccines–where we are today
WO2002046416A2 (fr) Immunogenes induisant une reponse des lymphocytes t cytotoxiques pour la prevention, le traitement et le diagnostic de cancers
Kaufman et al. Strategies for cancer therapy using carcinoembryonic antigen vaccines
JP2002500002A (ja) 癌胎児性抗原（ｃｅａ）のアゴニストおよびアンタゴニストペプチド
JP2007504154A (ja) ブラザー・オブ・レギュレーター・オブ・イムプリンテッド・サイト（ｂｏｒｉｓ）分子をベースにした癌予防ワクチン
EP1207199B1 (fr) Antigene de tumeur
Sarobe et al. Carcinoembryonic antigen as a target to induce anti-tumor immune responses
EP1444261B1 (fr) Peptides alk immunogeniques
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
WO2003093298A2 (fr) Peptides immunogenes
Van Pel et al. Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes
Tajima et al. Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA‐A* 2402‐restricted cytotoxic T‐lymphocyte responses
Schlom et al. Carcinoembryonic antigen as a vaccine target
US20100068263A1 (en) Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002787687

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002787687

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002787687

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP